KRAS Companion Test for Erbitux Wins OK
(MedPage Today) — A rapid molecular test for KRAS mutations has received FDA approval as an aid in identifying colorectal cancer patients who would benefit from cetuximab (Erbitux) treatment.
(MedPage Today) — A rapid molecular test for KRAS mutations has received FDA approval as an aid in identifying colorectal cancer patients who would benefit from cetuximab (Erbitux) treatment.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.